Skip to main content

Focus: Assess Post Infusion Viability of S303 RBCs

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Cerus
CerusCA - Concord
1 program
1
S303 Red Blood CellsPhase 21 trial
Active Trials
NCT01711346Completed42Est. Nov 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CerusS303 Red Blood Cells

Clinical Trials (1)

Total enrollment: 42 patients across 1 trials

NCT01711346CerusS303 Red Blood Cells

A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells

Start: Oct 2012Est. completion: Nov 201442 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.